EPA-E Composition for NASH Treatment via Omega-3 Ratio
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are inadequate for effectively slowing down or altering the progression of Non-Alcoholic Steatohepatitis (NASH), a condition characterized by fatty liver disease, inflammation, and potential scarring, with limited treatment options available.
Innovation Solution
Administration of a therapeutically effective amount of ethyl eicosapentanoate (EPA-E), which may comprise at least 40% of the fatty acids and derivatives, to subjects with NASH, particularly those who are non-diabetic, pre-diabetic, or mildly diabetic, and with normal or substantially normal biliary tract function, to improve serum markers and reduce liver inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional therapies are used for NASH, then treatment options are limited, but disease progression cannot be effectively slowed or altered
Solution Approach 1:
The patent applies parameter changes by modifying the fatty acid composition parameters in the dietary intervention. Specifically, it increases omega-3 fatty acids (EPA and DHA) to at least 1.8% of total calories and decreases omega-6 fatty acids to no more than 5.0% of total calories, creating a specific omega-3 to omega-6 ratio. This parameter modification in the diet composition leads to improved liver histology and reduced inflammation in NASH patients, effectively addressing the lack of reliable treatment options.
2Measurement precision
If liver biopsy is performed to diagnose NASH, then accurate characterization of liver histology is achieved, but invasive procedure risks and patient discomfort increase
Solution Approach 1:
The patent employs copying by using non-invasive imaging techniques (MRI, CT scans, ultrasound) and serum biomarker analysis to create surrogate measurements that replicate the diagnostic information obtained from invasive liver biopsy. These alternative methods capture the essential histological features of NASH (steatosis, inflammation, fibrosis) without requiring actual tissue sampling, thereby eliminating procedural risks while maintaining diagnostic accuracy for treatment monitoring purposes.
3Reliability
If fatty acid supplementation is increased to treat NASH, then anti-inflammatory effects improve, but potential interference with biliary tract function may occur
Solution Approach 1:
The patent applies local quality by tailoring the fatty acid supplementation regimen to specific patient subgroups based on their biliary tract function status. It identifies that patients with normal or substantially normal biliary tract function (indicated by normal GGT levels) derive the greatest benefit from high omega-3 supplementation. The treatment selectively targets this population, customizing the intervention to match the local physiological condition and maximize anti-inflammatory effects while avoiding potential biliary interference.
Data Source
AI summary
The disclosure provides for a method for treating a fatty liver disorder in a subject in need thereof, comprising selecting a subject having or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre-diabetic, mildly diabetic, or has normal or substantially normal biliary tract function; and administering a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E). In some cases EPA-E present may be at least 40% by weight in total of the fatty acids and their derivatives.